id,ticker,date,title,url
1,89bio,2024-03-12,89bio Initiates Phase 3 ENLIGHTEN-Fibrosis Trial of Pegozafermin in Non-Cirrhotic Metabolic Dysfunction-Associated Steatohepatitis (MASH) Patients with Fibrosis,https://ir.89bio.com/news-releases/news-release-details/89bio-initiates-phase-3-enlighten-fibrosis-trial-pegozafermin
2,89bio,2024-03-08,89bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4),https://ir.89bio.com/news-releases/news-release-details/89bio-announces-inducement-grant-under-nasdaq-listing-rule-0
3,89bio,2024-03-05,89bio to Participate in the Leerink Partners Global Biopharma Conference,https://ir.89bio.com/news-releases/news-release-details/89bio-participate-leerink-partners-global-biopharma-conference
4,Acumen Pharmaceuticals,2024-03-12,Acumen Pharmaceuticals to Participate in the Stifel 2024 CNS Days,https://investors.acumenpharm.com/news-releases/news-release-details/acumen-pharmaceuticals-participate-stifel-2024-cns-days
5,Acumen Pharmaceuticals,2024-03-08,Acumen Pharmaceuticals Presents Sabirnetug (ACU193) Fluid Biomarker and Target Engagement Analyses from Phase 1 INTERCEPT-AD Study in Early Alzheimer’s at the AD/PD™ 2024 Annual Meeting,https://investors.acumenpharm.com/news-releases/news-release-details/acumen-pharmaceuticals-presents-sabirnetug-acu193-fluid
6,Acumen Pharmaceuticals,2024-02-21,Acumen Pharmaceuticals to Present Sabirnetug (ACU193) Fluid Biomarker and Target Engagement Analyses from Phase 1 INTERCEPT-AD Study in Early Alzheimer’s at the AD/PD™ 2024 Annual Meeting,https://investors.acumenpharm.com/news-releases/news-release-details/acumen-pharmaceuticals-present-sabirnetug-acu193-fluid-biomarker
7,Alto Neuroscience,2024-03-11,"Alto Neuroscience Appoints Maha Radhakrishnan, M.D., to Board of Directors",https://investors.altoneuroscience.com/news/news-details/2024/Alto-Neuroscience-Appoints-Maha-Radhakrishnan-M.D.-to-Board-of-Directors/default.aspx
8,Alto Neuroscience,2024-03-07,Alto Neuroscience to Participate in Upcoming Investor Conferences,https://investors.altoneuroscience.com/news/news-details/2024/Alto-Neuroscience-to-Participate-in-Upcoming-Investor-Conferences/default.aspx
9,Alto Neuroscience,2024-02-27,Alto Neuroscience to Present at the TD Cowen 44th Annual Healthcare Conference,https://investors.altoneuroscience.com/news/news-details/2024/Alto-Neuroscience-to-Present-at-the-TD-Cowen-44th-Annual-Healthcare-Conference/default.aspx
10,Alto Neuroscience,2024-03-20,Stifel 2024 Virtual CNS Days,https://investors.altoneuroscience.com/events-and-presentations/event-details/2024/Stifel-2024-Virtual-CNS-Days/default.aspx
11,Alto Neuroscience,2024-03-18,UBS Virtual CNS Day 2024,https://investors.altoneuroscience.com/events-and-presentations/event-details/2024/Alto-Neuroscience-Inc--UBS-Virtual-CNS-Day-2024/default.aspx
12,Alto Neuroscience,2024-03-05,TD Cowen 44th Annual Health Care Conference,https://investors.altoneuroscience.com/events-and-presentations/event-details/2024/TD-Cowen-44th-Annual-Health-Care-Conference/default.aspx
13,ASLAN Pharmaceuticals,2024-03-13,ASLAN Pharmaceuticals Announces $5 Million Registered Direct Offering,https://ir.aslanpharma.com/news-releases/news-release-details/aslan-pharmaceuticals-announces-5-million-registered-direct
14,ASLAN Pharmaceuticals,2024-03-11,ASLAN Pharmaceuticals Provides TREK-DX Study Update and Highlights Potential of Eblasakimab in Dupilumab-Experienced Atopic Dermatitis Patients,https://ir.aslanpharma.com/news-releases/news-release-details/aslan-pharmaceuticals-provides-trek-dx-study-update-and
15,ASLAN Pharmaceuticals,2024-03-06,ASLAN Pharmaceuticals Announces New Translational Data on Eblasakimab in COPD and Appoints Leading Respiratory Experts as Scientific Advisors,https://ir.aslanpharma.com/news-releases/news-release-details/aslan-pharmaceuticals-announces-new-translational-data
16,Corbus Pharmaceuticals,2024-03-12,Corbus Pharmaceuticals Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update,https://ir.corbuspharma.com/press-releases/detail/409/corbus-pharmaceuticals-reports-fourth-quarter-and-year-end
17,Elevation Oncology,2024-03-06,Elevation Oncology Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Business Achievements,https://investors.elevationoncology.com/2024-03-06-Elevation-Oncology-Reports-Fourth-Quarter-and-Full-Year-2023-Financial-Results-and-Highlights-Recent-Business-Achievements
18,Elevation Oncology,2024-03-05,Elevation Oncology to Present Preclinical Proof-of-Concept Data for HER3-ADC Program at the American Association for Cancer Research (AACR) Annual Meeting 2024,https://investors.elevationoncology.com/2024-03-05-Elevation-Oncology-to-Present-Preclinical-Proof-of-Concept-Data-for-HER3-ADC-Program-at-the-American-Association-for-Cancer-Research-AACR-Annual-Meeting-2024
19,Elevation Oncology,2024-03-04,"Elevation Oncology Appoints Experienced Clinical Development Leaders Julie Cherrington, Ph.D. and Alan Sandler, M.D. to Board of Directors","https://investors.elevationoncology.com/2024-03-04-Elevation-Oncology-Appoints-Experienced-Clinical-Development-Leaders-Julie-Cherrington,-Ph-D-and-Alan-Sandler,-M-D-to-Board-of-Directors"
20,Inozyme,2024-03-12,Inozyme Pharma Reports Full Year 2023 Financial Results and Provides Business Highlights,https://investors.inozyme.com/news-releases/news-release-details/inozyme-pharma-reports-full-year-2023-financial-results-and
21,Inozyme,2024-02-26,Inozyme Pharma to Participate in the TD Cowen 44th Annual Health Care Conference,https://investors.inozyme.com/news-releases/news-release-details/inozyme-pharma-participate-td-cowen-44th-annual-health-care
22,Inozyme,2024-02-06,Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4),https://investors.inozyme.com/news-releases/news-release-details/inozyme-pharma-reports-inducement-grants-under-nasdaq-listing-5
23,Inspirna,2016-06-15,"Rgenix Raises $33M, Preps Cancer Trial For Drug Shelved By GSK",https://inspirna.com/rgenix-raises-33m-preps-cancer-trial-for-drug-shelved-by-gsk/
24,Inspirna,2016-06-15,"Rottweiler tested, Novo and Sofinnova back $33M round for Rgenix",https://inspirna.com/rottweiler-tested-novo-and-sofinnova-back-33m-round-for-rgenix/
25,Inspirna,2016-06-15,Rgenix Announces $33 Million Series B Financing to Develop First-in-Class Cancer Therapeutics,https://inspirna.com/rgenix-announces-33-million-series-b-financing-to-develop-first-in-class-cancer-therapeutics-2/
26,Inspirna,2015-08-31,"In New York, Rgenix Rises From Rockefeller and Takes Aim at Cancer",https://inspirna.com/in-new-york-rgenix-rises-from-rockefeller-and-takes-aim-at-cancer/
27,Inspirna,2024-01-04,Inspirna to Present at the 42nd Annual J.P. Morgan Healthcare Conference,https://inspirna.com/inspirna-to-present-at-the-42nd-annual-j-p-morgan-healthcare-conference/
28,Inspirna,2024-01-04,"Inspirna Partners with Merck KGaA, Darmstadt, Germany, to Accelerate Global Development of Ompenaclid (RGX-202)",https://inspirna.com/inspirna-partners-with-merck-kgaa-darmstadt-germany-to-accelerate-global-development-of-ompenaclid-rgx-202/
29,Inspirna,2023-10-23,Inspirna Announces Clinical Data from Phase 1b/2 Study of Ompenaclid (RGX-202) in Advanced Colorectal Cancer at ESMO Congress 2023,https://inspirna.com/inspirna-announces-clinical-data-from-phase-1b-2-study-of-ompenaclid-rgx-202-in-advanced-colorectal-cancer-at-esmo-congress-2023/
30,Inspirna,2023-10-16,Inspirna to Present Clinical Data from Phase 1b/2 Study of Ompenaclid (RGX-202) in Advanced Colorectal Cancer at ESMO Congress 2023,https://inspirna.com/inspirna-to-present-clinical-data-from-phase-1b-2-study-of-ompenaclid-rgx-202-in-advanced-colorectal-cancer-at-esmo-congress-2023/
31,Inspirna,2023-06-01,Inspirna to Present at the Jefferies Healthcare Conference,https://inspirna.com/inspirna-to-present-at-the-jefferies-healthcare-conference/
32,Inspirna,2023-05-01,"Inspirna Appoints Dr. Usman “Oz” Azam, M.D., as New Chief Executive Officer",https://inspirna.com/inspirna-appoints-dr-usman-oz-azam-m-d-as-new-chief-executive-officer/
33,Inspirna,2023-01-05,Inspirna Announces Interim Data from Phase 1b/2 Study of Abequolixron (RGX-104) in Relapsed or Refractory Lung Cancer,https://inspirna.com/inspirna-announces-interim-data-from-phase-1b-2-study-of-abequolixron-rgx-104-in-relapsed-or-refractory-lung-cancer/
34,Inspirna,2022-11-17,Inspirna to Present at the Evercore ISI Annual HealthCONx Conference,https://inspirna.com/inspirna-to-present-at-the-evercore-isi-annual-healthconx-conference/
35,Inspirna,2022-07-11,Inspirna Raises $50 Million in Series D Financing,https://inspirna.com/inspirna-raises-50-million-in-series-d-financing/
36,Inspirna,2022-06-28,Inspirna to Present Phase 1b RGX-202-01 Clinical Trial Data at the 2022 ESMO World Congress on Gastrointestinal Cancer,https://inspirna.com/inspirna-to-present-phase-1b-rgx-202-01-clinical-trial-data-at-the-2022-esmo-world-congress-on-gastrointestinal-cancer/
37,Inspirna,2022-05-26,Inspirna to Present Phase 1b RGX-202-01 Clinical Trial Data at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting,https://inspirna.com/inspirna-to-present-phase-1b-rgx-202-01-clinical-trial-data-at-the-2022-american-society-of-clinical-oncology-asco-annual-meeting/
38,Inspirna,2022-04-27,Inspirna Announces Phase 1b RGX-202 Clinical Trial Data Selected for Poster Presentation at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting,https://inspirna.com/inspirna-announces-phase-1b-rgx-202-clinical-trial-data-selected-for-poster-presentation-at-the-2022-american-society-of-clinical-oncology-asco-annual-meeting/
39,Inspirna,2022-04-07,Inspirna to Present at 21st Annual Needham Virtual Healthcare Conference,https://inspirna.com/inspirna-to-present-at-21st-annual-needham-virtual-healthcare-conference/
40,Inspirna,2022-03-08,Inspirna to Participate in Multiple Virtual Healthcare Investor Conferences in March,https://inspirna.com/inspirna-to-participate-in-multiple-virtual-healthcare-investor-conferences-in-march/
41,Inspirna,2021-12-09,Inspirna Strengthens Scientific Advisory Board with Two Globally Renowned Experts in Gastrointestinal Oncology,https://inspirna.com/inspirna-strengthens-scientific-advisory-board-with-two-globally-renowned-experts-in-gastrointestinal-oncology/
42,Inspirna,2021-11-22,Inspirna to Present at the Piper Sandler 33rd Annual Virtual Healthcare Conference,https://inspirna.com/inspirna-to-present-at-the-piper-sandler-33rd-annual-virtual-healthcare-conference/
43,Inspirna,2021-11-10,Inspirna to Present at the Stifel 2021 Virtual Healthcare Conference,https://inspirna.com/stifel-2021-virtual-healthcare-conference/
44,Inspirna,2021-11-04,Inspirna Announces Clinical Collaboration with Bristol Myers Squibb to Study RGX-104 in Combination with Yervoy® (ipilimumab) for Treatment of Metastatic Endometrial Cancer,https://inspirna.com/inspirna-announces-clinical-collaboration-with-bristol-myers-squibb-to-study-rgx-104-in-combination-with-yervoy-ipilimumab-for-treatment-of-metastatic-endometrial-cancer/
45,Inspirna,2021-09-30,RGENIX Announces Company Name Change to Inspirna and Expands Board of Directors with Appointment of Pharma Veteran Dieter Weinand,https://inspirna.com/rgenix-announces-company-name-change-to-inspirna-and-expands-board-of-directors-with-appointment-of-pharma-veteran-dieter-weinand/
46,Inspirna,2020-11-23,RGENIX to Present at Piper Sandler 32nd Annual Virtual Healthcare Conference,https://inspirna.com/rgenix-to-present-at-piper-sandler-32nd-annual-virtual-healthcare-conference/
47,Inspirna,2020-11-04,RGENIX to Present at 2020 Stifel Virtual Healthcare Conference,https://inspirna.com/rgenix-to-present-at-2020-stifel-virtual-healthcare-conference/
48,Inspirna,2020-09-02,RGENIX to Present at H.C. Wainwright 22nd Annual Global Investment Conference,https://inspirna.com/rgenix-to-present-at-h-c-wainwright-22nd-annual-global-investment-conference/
49,Inspirna,2020-08-05,RGENIX to Present at Multiple Virtual Healthcare Investor Conferences in August,https://inspirna.com/rgenix-to-present-at-multiple-virtual-healthcare-investor-conferences-in-august/
50,Inspirna,2020-06-22,RGENIX Presents Biomarker and Efficacy Results from Phase 1 Dose Escalation Cohorts of RGX-104 at the 2020 AACR Annual Meeting,https://inspirna.com/rgenix-presents-biomarker-and-efficacy-results-from-phase-1-dose-escalation-cohorts-of-rgx-104-at-the-2020-aacr-annual-meeting/
51,Inspirna,2020-06-22,RGENIX Presents Results from Preclinical Safety and Efficacy Studies of RGX-019 at the 2020 AACR Annual Meeting,https://inspirna.com/rgenix-presents-results-from-preclinical-safety-and-efficacy-studies-of-rgx-019-at-the-2020-aacr-annual-meeting/
52,Inspirna,2020-05-29,RGENIX Shows Clinical Activity of Novel Agent RGX-202 in Patients with KRAS Mutant Colorectal Cancer in Phase 1 Trial,https://inspirna.com/rgenix-shows-clinical-activity-of-novel-agent-rgx-202-in-patients-with-kras-mutant-colorectal-cancer-in-phase-1-trial/
53,Inspirna,2020-05-21,RGENIX To Present RGX-202 Phase I Data at 2020 ASCO Virtual Scientific Program,https://inspirna.com/rgenix-to-present-rgx-202-phase-i-data-at-2020-asco-virtual-scientific-program/
54,Inspirna,2020-04-27,RGENIX Presents Initial Results of Combination Trial of RGX-104 at the 2020 AACR Annual Meeting,https://inspirna.com/rgenix-presents-initial-results-of-combination-trial-of-rgx-104-at-the-2020-aacr-annual-meeting/
55,Inspirna,2020-02-26,Clinical Development of First-in-class Innate IO Agents,https://inspirna.com/clinical-development-of-first-in-class-innate-io-agents/
56,Inspirna,2019-12-13,Rgenix Cancer Therapeutics Company Focuses on RNA to Identify Novel Targets,https://inspirna.com/rgenix-cancer-therapeutics-company-focuses-on-rna-to-identify-novel-targets/
57,Inspirna,2019-10-16,Featured on In Vivo: “Rgenix: A Cancer Start-Up’s Resolve To Crack The Mystery Of Metastasis”,https://inspirna.com/featured-on-in-vivo-rgenix-a-cancer-start-ups-resolve-to-crack-the-mystery-of-metastasis/
58,Inspirna,2019-09-16,Rgenix Names Industry Veteran to Chief Medical Officer Role,https://inspirna.com/rgenix-names-industry-veteran-to-chief-medical-officer-role/
59,Inspirna,2019-04-03,Rgenix Presents Pre-Clinical Data on RGX-019 at the  2019 AACR Annual Meeting,https://inspirna.com/rgenix-presents-pre-clinical-data-on-rgx-019-at-the-2019-aacr-annual-meeting/
60,Inspirna,2019-04-01,Rgenix To Present Abstract on RGX-019 at the 2019 AACR Annual Meeting,https://inspirna.com/rgenix-to-present-abstract-on-rgx-019-at-the-2019-aacr-annual-meeting/
61,Inspirna,2019-02-01,Translational and Clinical Development Strategies for IO Agents Targeting the Innate Immune System,https://inspirna.com/translational-and-clinical-development-strategies-for-io-agents-targeting-the-innate-immune-system/
62,Inspirna,2018-12-14,Xconomy: New York Biotech – How to make it here,https://inspirna.com/new-york-biotech-how-to-make-it-here/
63,Inspirna,2018-11-30,Rgenix CEO Masoud Tavazoie Discusses Immune System Regulation in Cancer at Plenary Session during AACR Meeting,https://inspirna.com/rgenix-ceo-masoud-tavazoie-discusses-immune-system-regulation-in-cancer-at-plenary-session-during-aacr-meeting/
64,Inspirna,2018-11-27,Rgenix Appoints Serial Entrepreneur and Senior Executive Peter Van Vlasselaer to Board of Directors,https://inspirna.com/rgenix-appoints-serial-entrepreneur-and-senior-executive-peter-van-vlasselaer-to-board-of-directors/
65,Inspirna,2018-11-27,AACR Tumor Immunology and Immunotherapy Conference,https://inspirna.com/aacr-tumor-immunology-and-immunotherapy-conference/
66,Inspirna,2018-10-31,Rgenix Treats First Patient in Phase 1 Trial of RGX-202,https://inspirna.com/rgenix-treats-first-patient-in-phase-1-trial-of-rgx-202/
67,Inspirna,2018-10-09,Rgenix Raises $40M in Series C Funding To Support Clinical Stage Oncology Programs,https://inspirna.com/rgenix-raises-40m-in-series-c-funding-to-support-clinical-stage-oncology-programs/
68,Inspirna,2018-06-04,Rgenix Presents Data on Phase I Clinical Activity For RGX-104 at the 2018 ASCO Annual Meeting,https://inspirna.com/rgenix-presents-data-on-phase-i-clinical-activity-for-rgx-104-at-the-2018-asco-annual-meeting/
69,Inspirna,2018-05-31,Rgenix To Present Data on RGX-104 Clinical Activity at  2018 ASCO Annual Meeting,https://inspirna.com/rgenix-to-present-data-on-rgx-104-clinical-activity-at-2018-asco-annual-meeting/
70,Inspirna,2018-05-25,"Pharmacodynamic and clinical activity of RGX-104, a first-in-class immunotherapy targeting the liver-X nuclear hormone receptor (LXR), in patients with refractory malignancies",https://inspirna.com/pharmacodynamic-and-clinical-activity-of-rgx-104/
71,Inspirna,2018-01-11,Rgenix Announces Publication In Cell Demonstrating Activation of LXR/ApoE with RGX-104 Enhances Antitumor Immunity,https://inspirna.com/rgenix-announces-publication/
72,Inspirna,2017-11-17,Liver X Factor,https://inspirna.com/liver-x-factor/
73,Inspirna,2017-11-17,Rgenix Reports Phase I Data for Cancer Compound RGX-104,https://inspirna.com/rgenix-reports-phase-i-data-for-cancer-compound-rgx-104-2/
74,Inspirna,2017-10-30,Rgenix Reports Preliminary Phase 1a/b Clinical Data Demonstrating Immune-stimulatory Activity with RGX-104 in Advanced Cancer Patients,https://inspirna.com/rgenix-reports-preliminary-phase-1a-b-clinical-data-2/
75,Inspirna,2017-10-29,Rgenix Reports Preliminary Phase 1a/b,https://inspirna.com/rgenix-reports-preliminary-phase-1a-b/
76,Inspirna,2017-10-26,Rgenix to Present Early Clinical Data on RGX-104 at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics,https://inspirna.com/rgenix-to-present-early-clinical-data-on-rgx-104/
77,Inspirna,2017-10-09,Meet the 30 biotech leaders under 40 who are searching for breakthrough treatments and shaping the future of medicine,https://inspirna.com/meet-the-30-biotech-leaders-under-40/
78,Inspirna,2017-09-14,"For Rgenix CEO Masoud Tavazoie, fighting cancer is a family business",https://inspirna.com/for-rgenix-ceo-masoud-tavazoie-fighting-cancer-is-a-family-business/
79,Inspirna,2017-04-28,Rgenix Appoints Chief Medical Officer,https://inspirna.com/rgenix-appoints-chief-medical-officer/
80,Inspirna,2017-01-06,"Rgenix Announces Treatment of First Patient in Phase 1 Trial of RGX-104, its Lead Immuno-Oncology Therapeutic",https://inspirna.com/rgenix-announces-treatment-of-first-patient-in-phase-1-trial-of-rgx-104/
81,Inspirna,2016-06-29,What does it take to succeed as a New York biotech startup?,https://inspirna.com/rgenix-announces-33-million-series-b-financing-to-develop-first-in-class-cancer-therapeutics/
82,Inspirna,2016-06-15,"Rgenix Raises $33M, Preps Cancer Trial For Drug Shelved By GSK",https://inspirna.com/rgenix-raises-33m-preps-cancer-trial-for-drug-shelved-by-gsk/
83,Inspirna,2016-06-15,"Rottweiler tested, Novo and Sofinnova back $33M round for Rgenix",https://inspirna.com/rottweiler-tested-novo-and-sofinnova-back-33m-round-for-rgenix/
84,Inspirna,2016-06-15,Rgenix Announces $33 Million Series B Financing to Develop First-in-Class Cancer Therapeutics,https://inspirna.com/rgenix-announces-33-million-series-b-financing-to-develop-first-in-class-cancer-therapeutics-2/
85,Inspirna,2015-08-31,"In New York, Rgenix Rises From Rockefeller and Takes Aim at Cancer",https://inspirna.com/in-new-york-rgenix-rises-from-rockefeller-and-takes-aim-at-cancer/
86,Inspirna,2024-01-04,Inspirna to Present at the 42nd Annual J.P. Morgan Healthcare Conference,https://inspirna.com/inspirna-to-present-at-the-42nd-annual-j-p-morgan-healthcare-conference/
87,Inspirna,2024-01-04,"Inspirna Partners with Merck KGaA, Darmstadt, Germany, to Accelerate Global Development of Ompenaclid (RGX-202)",https://inspirna.com/inspirna-partners-with-merck-kgaa-darmstadt-germany-to-accelerate-global-development-of-ompenaclid-rgx-202/
88,Inspirna,2023-10-23,Inspirna Announces Clinical Data from Phase 1b/2 Study of Ompenaclid (RGX-202) in Advanced Colorectal Cancer at ESMO Congress 2023,https://inspirna.com/inspirna-announces-clinical-data-from-phase-1b-2-study-of-ompenaclid-rgx-202-in-advanced-colorectal-cancer-at-esmo-congress-2023/
89,Inspirna,2023-10-16,Inspirna to Present Clinical Data from Phase 1b/2 Study of Ompenaclid (RGX-202) in Advanced Colorectal Cancer at ESMO Congress 2023,https://inspirna.com/inspirna-to-present-clinical-data-from-phase-1b-2-study-of-ompenaclid-rgx-202-in-advanced-colorectal-cancer-at-esmo-congress-2023/
90,Inspirna,2023-06-01,Inspirna to Present at the Jefferies Healthcare Conference,https://inspirna.com/inspirna-to-present-at-the-jefferies-healthcare-conference/
91,Inspirna,2023-05-01,"Inspirna Appoints Dr. Usman “Oz” Azam, M.D., as New Chief Executive Officer",https://inspirna.com/inspirna-appoints-dr-usman-oz-azam-m-d-as-new-chief-executive-officer/
92,Inspirna,2023-01-05,Inspirna Announces Interim Data from Phase 1b/2 Study of Abequolixron (RGX-104) in Relapsed or Refractory Lung Cancer,https://inspirna.com/inspirna-announces-interim-data-from-phase-1b-2-study-of-abequolixron-rgx-104-in-relapsed-or-refractory-lung-cancer/
93,Inspirna,2022-11-17,Inspirna to Present at the Evercore ISI Annual HealthCONx Conference,https://inspirna.com/inspirna-to-present-at-the-evercore-isi-annual-healthconx-conference/
94,Inspirna,2022-07-11,Inspirna Raises $50 Million in Series D Financing,https://inspirna.com/inspirna-raises-50-million-in-series-d-financing/
95,Inspirna,2022-06-28,Inspirna to Present Phase 1b RGX-202-01 Clinical Trial Data at the 2022 ESMO World Congress on Gastrointestinal Cancer,https://inspirna.com/inspirna-to-present-phase-1b-rgx-202-01-clinical-trial-data-at-the-2022-esmo-world-congress-on-gastrointestinal-cancer/
96,Inspirna,2022-05-26,Inspirna to Present Phase 1b RGX-202-01 Clinical Trial Data at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting,https://inspirna.com/inspirna-to-present-phase-1b-rgx-202-01-clinical-trial-data-at-the-2022-american-society-of-clinical-oncology-asco-annual-meeting/
97,Inspirna,2022-04-27,Inspirna Announces Phase 1b RGX-202 Clinical Trial Data Selected for Poster Presentation at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting,https://inspirna.com/inspirna-announces-phase-1b-rgx-202-clinical-trial-data-selected-for-poster-presentation-at-the-2022-american-society-of-clinical-oncology-asco-annual-meeting/
98,Inspirna,2022-04-07,Inspirna to Present at 21st Annual Needham Virtual Healthcare Conference,https://inspirna.com/inspirna-to-present-at-21st-annual-needham-virtual-healthcare-conference/
99,Inspirna,2022-03-08,Inspirna to Participate in Multiple Virtual Healthcare Investor Conferences in March,https://inspirna.com/inspirna-to-participate-in-multiple-virtual-healthcare-investor-conferences-in-march/
100,Inspirna,2021-12-09,Inspirna Strengthens Scientific Advisory Board with Two Globally Renowned Experts in Gastrointestinal Oncology,https://inspirna.com/inspirna-strengthens-scientific-advisory-board-with-two-globally-renowned-experts-in-gastrointestinal-oncology/
101,Inspirna,2021-11-22,Inspirna to Present at the Piper Sandler 33rd Annual Virtual Healthcare Conference,https://inspirna.com/inspirna-to-present-at-the-piper-sandler-33rd-annual-virtual-healthcare-conference/
102,Inspirna,2021-11-10,Inspirna to Present at the Stifel 2021 Virtual Healthcare Conference,https://inspirna.com/stifel-2021-virtual-healthcare-conference/
103,Inspirna,2021-11-04,Inspirna Announces Clinical Collaboration with Bristol Myers Squibb to Study RGX-104 in Combination with Yervoy® (ipilimumab) for Treatment of Metastatic Endometrial Cancer,https://inspirna.com/inspirna-announces-clinical-collaboration-with-bristol-myers-squibb-to-study-rgx-104-in-combination-with-yervoy-ipilimumab-for-treatment-of-metastatic-endometrial-cancer/
104,Inspirna,2021-09-30,RGENIX Announces Company Name Change to Inspirna and Expands Board of Directors with Appointment of Pharma Veteran Dieter Weinand,https://inspirna.com/rgenix-announces-company-name-change-to-inspirna-and-expands-board-of-directors-with-appointment-of-pharma-veteran-dieter-weinand/
105,Inspirna,2020-11-23,RGENIX to Present at Piper Sandler 32nd Annual Virtual Healthcare Conference,https://inspirna.com/rgenix-to-present-at-piper-sandler-32nd-annual-virtual-healthcare-conference/
106,Inspirna,2020-11-04,RGENIX to Present at 2020 Stifel Virtual Healthcare Conference,https://inspirna.com/rgenix-to-present-at-2020-stifel-virtual-healthcare-conference/
107,Inspirna,2020-09-02,RGENIX to Present at H.C. Wainwright 22nd Annual Global Investment Conference,https://inspirna.com/rgenix-to-present-at-h-c-wainwright-22nd-annual-global-investment-conference/
108,Inspirna,2020-08-05,RGENIX to Present at Multiple Virtual Healthcare Investor Conferences in August,https://inspirna.com/rgenix-to-present-at-multiple-virtual-healthcare-investor-conferences-in-august/
109,Inspirna,2020-06-22,RGENIX Presents Biomarker and Efficacy Results from Phase 1 Dose Escalation Cohorts of RGX-104 at the 2020 AACR Annual Meeting,https://inspirna.com/rgenix-presents-biomarker-and-efficacy-results-from-phase-1-dose-escalation-cohorts-of-rgx-104-at-the-2020-aacr-annual-meeting/
110,Inspirna,2020-06-22,RGENIX Presents Results from Preclinical Safety and Efficacy Studies of RGX-019 at the 2020 AACR Annual Meeting,https://inspirna.com/rgenix-presents-results-from-preclinical-safety-and-efficacy-studies-of-rgx-019-at-the-2020-aacr-annual-meeting/
111,Inspirna,2020-05-29,RGENIX Shows Clinical Activity of Novel Agent RGX-202 in Patients with KRAS Mutant Colorectal Cancer in Phase 1 Trial,https://inspirna.com/rgenix-shows-clinical-activity-of-novel-agent-rgx-202-in-patients-with-kras-mutant-colorectal-cancer-in-phase-1-trial/
112,Inspirna,2020-05-21,RGENIX To Present RGX-202 Phase I Data at 2020 ASCO Virtual Scientific Program,https://inspirna.com/rgenix-to-present-rgx-202-phase-i-data-at-2020-asco-virtual-scientific-program/
113,Inspirna,2020-04-27,RGENIX Presents Initial Results of Combination Trial of RGX-104 at the 2020 AACR Annual Meeting,https://inspirna.com/rgenix-presents-initial-results-of-combination-trial-of-rgx-104-at-the-2020-aacr-annual-meeting/
114,Inspirna,2020-02-26,Clinical Development of First-in-class Innate IO Agents,https://inspirna.com/clinical-development-of-first-in-class-innate-io-agents/
115,Inspirna,2019-12-13,Rgenix Cancer Therapeutics Company Focuses on RNA to Identify Novel Targets,https://inspirna.com/rgenix-cancer-therapeutics-company-focuses-on-rna-to-identify-novel-targets/
116,Inspirna,2019-10-16,Featured on In Vivo: “Rgenix: A Cancer Start-Up’s Resolve To Crack The Mystery Of Metastasis”,https://inspirna.com/featured-on-in-vivo-rgenix-a-cancer-start-ups-resolve-to-crack-the-mystery-of-metastasis/
117,Inspirna,2019-09-16,Rgenix Names Industry Veteran to Chief Medical Officer Role,https://inspirna.com/rgenix-names-industry-veteran-to-chief-medical-officer-role/
118,Inspirna,2019-04-03,Rgenix Presents Pre-Clinical Data on RGX-019 at the  2019 AACR Annual Meeting,https://inspirna.com/rgenix-presents-pre-clinical-data-on-rgx-019-at-the-2019-aacr-annual-meeting/
119,Inspirna,2019-04-01,Rgenix To Present Abstract on RGX-019 at the 2019 AACR Annual Meeting,https://inspirna.com/rgenix-to-present-abstract-on-rgx-019-at-the-2019-aacr-annual-meeting/
120,Inspirna,2019-02-01,Translational and Clinical Development Strategies for IO Agents Targeting the Innate Immune System,https://inspirna.com/translational-and-clinical-development-strategies-for-io-agents-targeting-the-innate-immune-system/
121,Inspirna,2018-12-14,Xconomy: New York Biotech – How to make it here,https://inspirna.com/new-york-biotech-how-to-make-it-here/
122,Inspirna,2018-11-30,Rgenix CEO Masoud Tavazoie Discusses Immune System Regulation in Cancer at Plenary Session during AACR Meeting,https://inspirna.com/rgenix-ceo-masoud-tavazoie-discusses-immune-system-regulation-in-cancer-at-plenary-session-during-aacr-meeting/
123,Inspirna,2018-11-27,Rgenix Appoints Serial Entrepreneur and Senior Executive Peter Van Vlasselaer to Board of Directors,https://inspirna.com/rgenix-appoints-serial-entrepreneur-and-senior-executive-peter-van-vlasselaer-to-board-of-directors/
124,Inspirna,2018-11-27,AACR Tumor Immunology and Immunotherapy Conference,https://inspirna.com/aacr-tumor-immunology-and-immunotherapy-conference/
125,Inspirna,2018-10-31,Rgenix Treats First Patient in Phase 1 Trial of RGX-202,https://inspirna.com/rgenix-treats-first-patient-in-phase-1-trial-of-rgx-202/
126,Inspirna,2018-10-09,Rgenix Raises $40M in Series C Funding To Support Clinical Stage Oncology Programs,https://inspirna.com/rgenix-raises-40m-in-series-c-funding-to-support-clinical-stage-oncology-programs/
127,Inspirna,2018-06-04,Rgenix Presents Data on Phase I Clinical Activity For RGX-104 at the 2018 ASCO Annual Meeting,https://inspirna.com/rgenix-presents-data-on-phase-i-clinical-activity-for-rgx-104-at-the-2018-asco-annual-meeting/
128,Inspirna,2018-05-31,Rgenix To Present Data on RGX-104 Clinical Activity at  2018 ASCO Annual Meeting,https://inspirna.com/rgenix-to-present-data-on-rgx-104-clinical-activity-at-2018-asco-annual-meeting/
129,Inspirna,2018-05-25,"Pharmacodynamic and clinical activity of RGX-104, a first-in-class immunotherapy targeting the liver-X nuclear hormone receptor (LXR), in patients with refractory malignancies",https://inspirna.com/pharmacodynamic-and-clinical-activity-of-rgx-104/
130,Inspirna,2018-01-11,Rgenix Announces Publication In Cell Demonstrating Activation of LXR/ApoE with RGX-104 Enhances Antitumor Immunity,https://inspirna.com/rgenix-announces-publication/
131,Inspirna,2017-11-17,Liver X Factor,https://inspirna.com/liver-x-factor/
132,Inspirna,2017-11-17,Rgenix Reports Phase I Data for Cancer Compound RGX-104,https://inspirna.com/rgenix-reports-phase-i-data-for-cancer-compound-rgx-104-2/
133,Inspirna,2017-10-30,Rgenix Reports Preliminary Phase 1a/b Clinical Data Demonstrating Immune-stimulatory Activity with RGX-104 in Advanced Cancer Patients,https://inspirna.com/rgenix-reports-preliminary-phase-1a-b-clinical-data-2/
134,Inspirna,2017-10-29,Rgenix Reports Preliminary Phase 1a/b,https://inspirna.com/rgenix-reports-preliminary-phase-1a-b/
135,Inspirna,2017-10-26,Rgenix to Present Early Clinical Data on RGX-104 at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics,https://inspirna.com/rgenix-to-present-early-clinical-data-on-rgx-104/
136,Inspirna,2017-10-09,Meet the 30 biotech leaders under 40 who are searching for breakthrough treatments and shaping the future of medicine,https://inspirna.com/meet-the-30-biotech-leaders-under-40/
137,Inspirna,2017-09-14,"For Rgenix CEO Masoud Tavazoie, fighting cancer is a family business",https://inspirna.com/for-rgenix-ceo-masoud-tavazoie-fighting-cancer-is-a-family-business/
138,Inspirna,2017-04-28,Rgenix Appoints Chief Medical Officer,https://inspirna.com/rgenix-appoints-chief-medical-officer/
139,Inspirna,2017-01-06,"Rgenix Announces Treatment of First Patient in Phase 1 Trial of RGX-104, its Lead Immuno-Oncology Therapeutic",https://inspirna.com/rgenix-announces-treatment-of-first-patient-in-phase-1-trial-of-rgx-104/
140,Inspirna,2016-06-29,What does it take to succeed as a New York biotech startup?,https://inspirna.com/rgenix-announces-33-million-series-b-financing-to-develop-first-in-class-cancer-therapeutics/
141,Inspirna,2016-06-15,"Rgenix Raises $33M, Preps Cancer Trial For Drug Shelved By GSK",https://inspirna.com/rgenix-raises-33m-preps-cancer-trial-for-drug-shelved-by-gsk/
142,Inspirna,2016-06-15,"Rottweiler tested, Novo and Sofinnova back $33M round for Rgenix",https://inspirna.com/rottweiler-tested-novo-and-sofinnova-back-33m-round-for-rgenix/
143,Inspirna,2016-06-15,Rgenix Announces $33 Million Series B Financing to Develop First-in-Class Cancer Therapeutics,https://inspirna.com/rgenix-announces-33-million-series-b-financing-to-develop-first-in-class-cancer-therapeutics-2/
144,Inspirna,2015-08-31,"In New York, Rgenix Rises From Rockefeller and Takes Aim at Cancer",https://inspirna.com/in-new-york-rgenix-rises-from-rockefeller-and-takes-aim-at-cancer/
145,MindMed,2024-03-11,MindMed to Participate in the Leerink Partners 2024 Global Biopharma Conference,https://ir.mindmed.co/news-events/press-releases/detail/139/mindmed-to-participate-in-the-leerink-partners-2024-global-biopharma-conference
146,MindMed,2024-03-07,Mind Medicine (MindMed) Inc. Announces Pricing of Underwritten Offering of Common Shares and Concurrent Private Placement,https://ir.mindmed.co/news-events/press-releases/detail/138/mind-medicine-mindmed-inc-announces-pricing-of-underwritten-offering-of-common-shares-and-concurrent-private-placement
147,MindMed,2024-03-07,MindMed Receives FDA Breakthrough Therapy Designation and Announces Positive 12-Week Durability Data From Phase 2B Study of MM120 for Generalized Anxiety Disorder,https://ir.mindmed.co/news-events/press-releases/detail/137/mindmed-receives-fda-breakthrough-therapy-designation-and-announces-positive-12-week-durability-data-from-phase-2b-study-of-mm120-for-generalized-anxiety-disorder
148,Molecular Templates,2024-03-04,"Molecular Templates, Inc. Provides Interim Update",https://www.mtem.com/investors/news-events-DQFwMCk3/press-releases-Ke9B82cd/detail/135/molecular-templates-inc-provides-interim-update
149,Molecular Templates,2024-02-08,Molecular Templates to Present at Oppenheimer 34th Annual Healthcare Life Sciences Conference,https://www.mtem.com/investors/news-events-DQFwMCk3/press-releases-Ke9B82cd/detail/134/molecular-templates-to-present-at-oppenheimer-34th-annual
150,Molecular Templates,2023-11-13,"Molecular Templates, Inc. Reports Third Quarter 2023 Financial Results and Business Update",https://www.mtem.com/investors/news-events-DQFwMCk3/press-releases-Ke9B82cd/detail/133/molecular-templates-inc-reports-third-quarter-2023
151,Ribon Therapeutics,2023-03-09,Ribon Therapeutics Doses First Patient in Phase 1 Clinical Study with RBN-3143 in Patients with Moderate-to-Severe Atopic Dermatitis,https://ribontx.com/ribon-therapeutics-doses-first-patient-in-phase-1-clinical-study-with-rbn-3143-in-patients-with-moderate-to-severe-atopic-dermatitis/
152,Ribon Therapeutics,2023-01-30,Ribon Therapeutics Announces $25 Million Equity Investment from Pfizer,https://ribontx.com/ribon-therapeutics-announces-25-million-equity-investment-from-pfizer/
153,Ribon Therapeutics,2022-11-29,Ribon Therapeutics Announces Acquisition of Pre-Clinical CD38 Program by Boehringer Ingelheim,https://ribontx.com/ribon-therapeutics-announces-acquisition-of-pre-clinical-cd38-program-by-boehringer-ingelheim/
154,Ribon Therapeutics,2022-09-06,Ribon Therapeutics Announces Late-Breaking Presentation of Preclinical Data on RBN-3143 at the European Respiratory Society International Congress 2022,https://ribontx.com/ribon-therapeutics-announces-late-breaking-presentation-of-preclinical-data-on-rbn-3143-at-the-european-respiratory-society-international-congress-2022/
155,Ribon Therapeutics,2022-04-11,Ribon Therapeutics Announces Presentations at the American Association for Cancer Research 2022 Annual Meeting,https://ribontx.com/ribon-therapeutics-announces-presentations-at-the-american-association-for-cancer-research-2022-annual-meeting/
156,Ribon Therapeutics,2022-03-29,Ribon Therapeutics Announces Initiation of Phase 1b/2 Study of RBN-2397 in Combination with Pembrolizumab in Patients with Squamous Cell Carcinoma of the Lung,https://ribontx.com/ribon-therapeutics-announces-initiation-of-phase-1b-2-study-of-rbn-2397-in-combination-with-pembrolizumab-in-patients-with-squamous-cell-carcinoma-of-the-lung/
157,Ribon Therapeutics,2022-03-22,Ribon Therapeutics Initiates First-in-Human Phase 1 Clinical Study of RBN-3143 for the Treatment of Atopic Dermatitis,https://ribontx.com/ribon-therapeutics-initiates-first-in-human-phase-1-clinical-study-of-rbn-3143-for-the-treatment-of-atopic-dermatitis/
158,Ribon Therapeutics,2022-02-17,"Ribon Therapeutics, a Clinical Stage Biotechnology Company Targeting Stress Support Pathways in Cancer and Inflammation, Announces CEO Transition for Its Next Phase of Growth",https://ribontx.com/ribon-therapeutics-a-clinical-stage-biotechnology-company-targeting-stress-support-pathways-in-cancer-and-inflammation-announces-ceo-transition-for-its-next-phase-of-growth/
159,Ribon Therapeutics,2021-09-27,Ribon Therapeutics Named a “Fierce 15” Biotech Company by Fierce Biotech,https://ribontx.com/ribon-therapeutics-named-a-fierce-15-biotech-company-by-fierce-biotech/
160,Ribon Therapeutics,2021-09-01,Ribon Therapeutics Announces Key Management Promotions,https://ribontx.com/ribon-therapeutics-announces-key-management-promotions/
161,Ribon Therapeutics,2021-07-22,Ribon Therapeutics Announces Publication in Cancer Cell of Pre-Clinical and Mechanism of Action Data for RBN-2397,https://ribontx.com/ribon-therapeutics-announces-publication-in-cancer-cell-of-pre-clinical-and-mechanism-of-action-data-for-rbn-2397/
162,Ribon Therapeutics,2021-07-14,Ribon Therapeutics Secures $65 Million Financing,https://ribontx.com/ribon-therapeutics-secures-65-million-financing/
163,Ribon Therapeutics,2021-06-28,Ribon Therapeutics Appoints Paul Brannelly as Chief Financial Officer,https://ribontx.com/ribon-therapeutics-appoints-paul-brannelly-as-chief-financial-officer/
164,Ribon Therapeutics,2021-06-04,Ribon Therapeutics Announces Oral Presentation of Positive Interim Data from Phase 1 Trial of RBN-2397 in Patients with Advanced Solid Tumors at 2021 ASCO Annual Meeting,https://ribontx.com/ribon-therapeutics-announces-oral-presentation-of-positive-interim-data-from-phase-1-trial-of-rbn-2397-in-patients-with-advanced-solid-tumors-at-2021-asco-annual-meeting/
165,Ribon Therapeutics,2021-05-20,Ribon Therapeutics Announces Oral Presentation of RBN-2397 Clinical Data at 2021 ASCO Annual Meeting,https://ribontx.com/ribon-therapeutics-announces-oral-presentation-of-rbn-2397-clinical-data-at-2021-asco-annual-meeting/
166,Ribon Therapeutics,2021-04-29,Ribon Therapeutics Announces Upcoming Presentation on RBN-2397 at the 2021 ASCO Annual Meeting,https://ribontx.com/ribon-therapeutics-announces-upcoming-presentation-on-rbn-2397-at-the-2021-asco-annual-meeting/
167,Ribon Therapeutics,2021-04-06,Ribon Therapeutics Announces Upcoming Presentations at the AACR 2021 Virtual Annual Meeting,https://ribontx.com/ribon-therapeutics-announces-upcoming-presentations-at-the-aacr-2021-virtual-annual-meeting/
168,Ribon Therapeutics,2021-02-02,"Ribon Therapeutics Announces License Agreement with Ono Pharmaceutical Co., Ltd. to Develop and Commercialize RBN-2397 In Japan, South Korea, Taiwan and ASEAN Countries",https://ribontx.com/ribon-therapeutics-announces-license-agreement-with-ono-pharmaceutical-co-ltd-to-develop-and-commercialize-rbn-2397-in-japan-south-korea-taiwan-and-asean-countries/
169,Ribon Therapeutics,2020-11-16,Ribon Therapeutics to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference,https://ribontx.com/ribon-therapeutics-to-present-at-the-piper-sandler-32nd-annual-virtual-healthcare-conference/
170,Ribon Therapeutics,2020-11-09,Ribon Therapeutics Announces the Appointment of Emma Reeve to the Company’s Board of Directors,https://ribontx.com/ribon-therapeutics-announces-the-appointment-of-emma-reeve-to-the-companys-board-of-directors/
171,Ribon Therapeutics,2020-07-16,Ribon Therapeutics Announces Appointment of Jodie P. Morrison as Chair of the Company’s Board of Directors,https://ribontx.com/ribon-therapeutics-announces-appointment-of-jodie-p-morrison-as-chair-of-the-companys-board-of-directors/
172,Ribon Therapeutics,2020-06-22,Ribon Therapeutics Presents Additional Preclinical Data on its PARP7 Inhibitor – RBN-2397 – and Demonstrates Broad Potential of its Platform at the AACR 2020 Virtual Meeting II,https://ribontx.com/ribon-therapeutics-presents-additional-preclinical-data-on-its-parp7-inhibitor-rbn-2397-and-demonstrates-broad-potential-of-its-platform-at-the-aacr-2020-virtual-meeting-ii/
173,Ribon Therapeutics,2020-05-26,Ribon Therapeutics to Present at the Jefferies Virtual Healthcare Conference,https://ribontx.com/ribon-therapeutics-to-present-at-the-jefferies-virtual-healthcare-conference/
174,Ribon Therapeutics,2020-05-15,Ribon Therapeutics to Present New Preclinical Data on its PARP7 Inhibitor – RBN-2397 – and its Discovery Platform at the Upcoming AACR 2020 Virtual Meeting II,https://ribontx.com/ribon-therapeutics-to-present-new-preclinical-data-on-its-parp7-inhibitor-rbn-2397-and-its-discovery-platform-at-the-upcoming-aacr-2020-virtual-meeting-ii/
175,Ribon Therapeutics,2020-05-04,Ribon Therapeutics to Present at Upcoming Healthcare Conferences,https://ribontx.com/ribon-therapeutics-to-present-at-upcoming-healthcare-conferences/
176,Ribon Therapeutics,2020-04-27,Ribon Therapeutics Presents Preclinical Data from its PARP7 and PARP14 Programs at AACR Virtual Meeting I,https://ribontx.com/ribon-therapeutics-presents-preclinical-data-from-its-parp7-and-parp14-programs-at-aacr-virtual-meeting-i/
177,Ribon Therapeutics,2020-04-14,Ribon Therapeutics to Present New Preclinical Data at the Upcoming AACR Virtual Annual Meetings,https://ribontx.com/ribon-therapeutics-to-present-new-preclinical-data-at-the-upcoming-aacr-virtual-annual-meetings/
178,Ribon Therapeutics,2020-01-24,Ribon Therapeutics to Present at Upcoming Scientific Conferences,https://ribontx.com/ribon-therapeutics-to-present-at-upcoming-scientific-conferences/
179,Ribon Therapeutics,2020-01-06,Ribon Therapeutics Named as a Top Life Sciences Company to Watch in 2020,https://www.biospace.com/article/top-21-life-science-startups-to-watch-in-2020/
180,Ribon Therapeutics,2019-12-18,"Ribon Therapeutics Strengthens Scientific Advisory Board with Appointment of Neal Rosen, M.D., Ph.D.",https://ribontx.com/ribon-therapeutics-strengthens-scientific-advisory-board-with-appointment-of-neal-rosen-m-d-ph-d/
181,Ribon Therapeutics,2019-09-04,"Ribon Therapeutics Announces Dosing of First Patient in Phase 1 Clinical Trial of RBN-2397, a First-In-Class PARP7 Inhibitor",https://ribontx.com/ribon-therapeutics-announces-dosing-of-first-patient-in-phase-1-clinical-trial-of-rbn-2397-a-first-in-class-parp7-inhibitor/
182,Ribon Therapeutics,2019-08-06,"Ribon Therapeutics Strengthens Management Team with Appointment of Sudha Parasuraman, M.D., as Chief Medical Officer and Edward Stewart as Chief Business Officer",https://ribontx.com/ribon-therapeutics-strengthens-management-team-with-appointment-of-sudha-parasuraman-m-d-as-chief-medical-officer-and-edward-stewart-as-chief-business-officer/
183,Ribon Therapeutics,2019-01-04,Ribon Therapeutics Raises $65 Million to Advance Pipeline of Novel Therapeutics Targeting Cellular Stress Pathways for Cancer,https://ribontx.com/ribon-press-release/
184,Tscan Therapeutics,2024-03-06,TScan Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update,https://ir.tscan.com/news-releases/news-release-details/tscan-therapeutics-reports-fourth-quarter-and-full-year-2023
185,Tscan Therapeutics,2024-02-28,TScan Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference,https://ir.tscan.com/news-releases/news-release-details/tscan-therapeutics-participate-td-cowen-44th-annual-health-care
186,Tscan Therapeutics,2024-02-26,TScan Therapeutics Presents Promising Updated Phase 1 Clinical Results on TSC-100 and TSC-101 at the 2024 Tandem Meetings of ASTCT and CIBMTR,https://ir.tscan.com/news-releases/news-release-details/tscan-therapeutics-presents-promising-updated-phase-1-clinical
187,VBI Vaccines,2024-02-14,"VBI Announces Agreement to Sell Manufacturing Capabilities, Certain Related Assets, and Enter Into New License Agreement with Brii Biosciences",https://www.vbivaccines.com/press-releases/vbi-announces-agreement-to-sell-manufacturing-capabilities-certain-related-assets-and-enter-into-new-license-agreement-with-brii-biosciences/
188,VBI Vaccines,2023-11-20,VBI Vaccines Presents Additional Biomarker Data from Phase 1/2a Study of VBI-1901 in Recurrent GBM at the 2023 Society for Neuro-Oncology (SNO) Annual Meeting,https://www.vbivaccines.com/press-releases/vbi-vaccines-presents-additional-biomarker-data-from-phase-1-2a-study-of-vbi-1901-in-recurrent-gbm-at-the-2023-society-for-neuro-oncology-sno-annual-meeting/
189,VBI Vaccines,2023-11-14,VBI Vaccines Reports Third Quarter 2023 Financial Results,https://www.vbivaccines.com/press-releases/vbi-vaccines-reports-third-quarter-2023-financial-results/
190,VBI Vaccines,2023-10-26,VBI Vaccines Expands Proprietary Technology Platforms With Development of a Novel mRNA-Launched eVLP Vaccine Program,https://www.vbivaccines.com/press-releases/vbi-vaccines-expands-proprietary-technology-platforms-with-development-of-a-novel-mrna-launched-evlp-vaccine-program/
191,VBI Vaccines,2023-09-27,"VBI Vaccines’ Pan-Coronavirus Vaccine Candidate, VBI-2901, Induced Broad and Durable Protective Titers Against Variants of Concern",https://www.vbivaccines.com/press-releases/vbi-vaccines-pan-coronavirus-vaccine-candidate-vbi-2901-induced-broad-and-durable-protective-titers-against-variants-of-concern/
192,VBI Vaccines,2023-09-07,VBI Vaccines Announces Dosing of First Patients in Phase 2b Study of VBI-1901 in Recurrent GBM,https://www.vbivaccines.com/press-releases/vbi-vaccines-announces-dosing-of-first-patients-in-phase-2b-study-of-vbi-1901-in-recurrent-gbm/
193,VBI Vaccines,2023-09-06,VBI Vaccines Partner Brii Biosciences Announces Topline Interim Results of Phase 2 Study Evaluating BRII-179 (VBI-2601) in Combination With PEG-IFNα for the Treatment of Chronic Hepatitis B,https://www.vbivaccines.com/press-releases/vbi-vaccines-partner-brii-biosciences-announces-topline-interim-results-of-phase-2-study-evaluating-brii-179-vbi-2601-in-combination-with-peg-ifn-for-the-treatment-of-chronic-hepatitis-b/
194,VBI Vaccines,2023-08-14,VBI Vaccines Reports Second Quarter 2023 Financial Results,https://www.vbivaccines.com/press-releases/vbi-vaccines-reports-second-quarter-2023-financial-results/
195,VBI Vaccines,2023-07-24,VBI Vaccines Announces Closing of Underwriters’ Partial Exercise of Option to Purchase Additional Common Shares,https://www.vbivaccines.com/press-releases/vbi-vaccines-announces-closing-of-underwriters-partial-exercise-of-option-to-purchase-additional-common-shares/
196,VBI Vaccines,2023-07-19,VBI Vaccines Announces PreHevbri® is Now Available in the Netherlands and Belgium for the Prevention of Hepatitis B in Adults,https://www.vbivaccines.com/press-releases/vbi-vaccines-announces-prehevbri-is-now-available-in-the-netherlands-and-belgium-for-the-prevention-of-hepatitis-b-in-adults/
197,VBI Vaccines,2023-07-06,VBI Vaccines Announces Pricing of $18 Million Public Offering and $3 Million Concurrent Registered Direct Offering,https://www.vbivaccines.com/press-releases/vbi-vaccines-announces-pricing-of-18-million-public-offering-and-3-million-concurrent-registered-direct-offering/
198,VBI Vaccines,2023-07-05,VBI Vaccines Announces Proposed Concurrent Public Offering and Registered Direct Offering of Common Shares and Warrants,https://www.vbivaccines.com/press-releases/proposed-concurrent-public-offering-and-registered-direct-offering-of-common-shares-and-warrants-june-2023/
199,VBI Vaccines,2023-07-05,VBI Vaccines and Brii Biosciences Expand Hepatitis B Partnership To Address Both Prevention and Treatment in License and Collaboration Agreements for up to $437 Million Plus Royalties,https://www.vbivaccines.com/press-releases/vbi-vaccines-and-brii-biosciences-expand-hepatitis-b-partnership-to-address-both-prevention-and-treatment-in-license-and-collaboration-agreements-for-up-to-437-million-plus-royalties/
200,VBI Vaccines,2023-06-23,VBI Vaccines Announces Results of Annual General Meeting,https://www.vbivaccines.com/press-releases/vbi-vaccines-announces-results-of-annual-general-meeting-2023/
201,VBI Vaccines,2023-06-15,VBI Vaccines Announces PreHevbri® is Now Available in the United Kingdom for the Prevention of Hepatitis B in Adults,https://www.vbivaccines.com/press-releases/vbi-vaccines-announces-prehevbri-is-now-available-in-the-united-kingdom-for-the-prevention-of-hepatitis-b-in-adults/
202,VBI Vaccines,2023-06-07,VBI Vaccines Announces Poster Presentation at EASL 2023,https://www.vbivaccines.com/press-releases/easl-2023/
203,VBI Vaccines,2023-05-15,VBI Vaccines Reports First Quarter 2023 Financial Results,https://www.vbivaccines.com/press-releases/vbi-vaccines-reports-first-quarter-2023-financial-results/
204,VBI Vaccines,2023-04-25,VBI Vaccines Appoints Vaughn Himes to Board of Directors,https://www.vbivaccines.com/press-releases/vbi-vaccines-appoints-vaughn-himes-to-board-of-directors/
205,VBI Vaccines,2023-04-04,"VBI Vaccines Announces Increased Focus on Hepatitis B, Organizational Changes, and Reverse Stock Split",https://www.vbivaccines.com/press-releases/increased-focus-on-hepatitis-b-organizational-changes-and-reverse-stock-split/
206,VBI Vaccines,2023-03-13,VBI Vaccines Reports Full Year 2022 Financial Results,https://www.vbivaccines.com/press-releases/2022-results/
207,Vedanta Biosciences,2024-03-06,Vedanta Biosciences to Host Investor Meetings at the Leerink Partners 2024 Global Biopharma Conference,https://www.vedantabio.com/news-media/press-releases/detail/3098/vedanta-biosciences-to-host-investor-meetings-at-the
